Acute Myeloid Leukemia, in Relapse

Oncology
6
Pipeline Programs
6
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Peptide
133%
+ 3 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Advesya
AdvesyaFrance - Paris
1 program
1
CCTx-001Phase 1/21 trial
Active Trials
NCT06281847Not Yet RecruitingEst. Aug 2041
Bio-Path Holdings
Bio-Path HoldingsBELLAIRE, TX
1 program
1
BP1002; Liposomal Bcl-2 Antisense OligodeoxynucleotidePhase 1Peptide1 trial
Active Trials
NCT05190471RecruitingEst. Sep 2027
Caribou Biosciences
1 program
1
CB-012Phase 11 trial
Active Trials
NCT06128044Terminated12Est. May 2025
Genomics
GenomicsUK - Oxford
1 program
1
IadademstatPhase 1Small Molecule1 trial
Active Trials
NCT05546580Recruiting50Est. Nov 2025
Oryzon Genomics
Oryzon GenomicsMA - Cambridge
1 program
1
IadademstatPhase 1Small Molecule
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
MT-401-OTSPhase 11 trial
Active Trials
NCT06552416Recruiting40Est. Sep 2029

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AdvesyaCCTx-001
City TherapeuticsMT-401-OTS
Caribou BiosciencesCB-012
GenomicsIadademstat
Bio-Path HoldingsBP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

Clinical Trials (5)

Total enrollment: 102 patients across 5 trials

NCT06281847AdvesyaCCTx-001

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Start: Dec 2025Est. completion: Aug 2041
Phase 1/2Not Yet Recruiting
NCT06552416City TherapeuticsMT-401-OTS

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Start: Jun 2025Est. completion: Sep 202940 patients
Phase 1Recruiting
NCT06128044Caribou BiosciencesCB-012

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start: Feb 2024Est. completion: May 202512 patients
Phase 1Terminated
NCT05546580GenomicsIadademstat

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Start: Nov 2022Est. completion: Nov 202550 patients
Phase 1Recruiting
NCT05190471Bio-Path HoldingsBP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Start: Aug 2022Est. completion: Sep 2027
Phase 1Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
18m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
18m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 102 patients
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)